Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer
Adam C Mueller,Miles Piper,Andrew Goodspeed,Shiv Bhuvane,Jason S Williams,Shilpa Bhatia,Andy V Phan,Benjamin Van Court,Kathryn L Zolman,Brisa Peña,Ayman J Oweida,Sara Zakem,Cheryl Meguid,Michael W Knitz,Laurel Darragh,Thomas E Bickett,Jacob Gadwa,Luisa Mestroni,Matthew R G Taylor,Kimberly R Jordan,Peter Dempsey,M Scott Lucia,Martin D McCarter,Marco Del Chiaro,Wells A Messersmith,Richard D Schulick,Karyn A Goodman,Michael J Gough,Casey S Greene,James C Costello,Antonio Galveo Neto,David Lagares,Kirk C Hansen,Adrie Van Bokhoven,Sana D Karam
DOI: https://doi.org/10.1158/0008-5472.CAN-20-3892
2021-06-15
Abstract:Stromal fibrosis activates prosurvival and proepithelial-to-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma (PDAC). In patient tumors treated with neoadjuvant stereotactic body radiation therapy (SBRT), we found upregulation of fibrosis, extracellular matrix (ECM), and EMT gene signatures, which can drive therapeutic resistance and tumor invasion. Molecular, functional, and translational analysis identified two cell-surface proteins, a disintegrin and metalloprotease 10 (ADAM10) and ephrinB2, as drivers of fibrosis and tumor progression after radiation therapy (RT). RT resulted in increased ADAM10 expression in tumor cells, leading to cleavage of ephrinB2, which was also detected in plasma. Pharmacologic or genetic targeting of ADAM10 decreased RT-induced fibrosis and tissue tension, tumor cell migration, and invasion, sensitizing orthotopic tumors to radiation killing and prolonging mouse survival. Inhibition of ADAM10 and genetic ablation of ephrinB2 in fibroblasts reduced the metastatic potential of tumor cells after RT. Stimulation of tumor cells with ephrinB2 FC protein reversed the reduction in tumor cell invasion with ADAM10 ablation. These findings represent a model of PDAC adaptation that explains resistance and metastasis after RT and identifies a targetable pathway to enhance RT efficacy. SIGNIFICANCE: Targeting a previously unidentified adaptive resistance mechanism to radiation therapy in PDAC tumors in combination with radiation therapy could increase survival of the 40% of PDAC patients with locally advanced disease.See related commentary by Garcia Garcia et al., p. 3158 GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/12/3255/F1.large.jpg.